Loading
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Previous close
$10.49
+$0.73 · +7.48%
After-hours
$10.49
$0.00 · 0.00%
Oct 7, 5:35 PM ET
Regular session · ET · Market data may be delayed.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Day range
Current $10.49
52-week range
Current $10.49
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
52
Fair Value
Sentiment
49
Mixed
Risk
78
High Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Day range
Current $10.49
52-week range
Current $10.49
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.39M USD | 2.27M USD | — | — | — |
| Cost of goods sold | 4.28M USD | — | — | — | — |
| Gross profit | 2.11M USD | 2.27M USD | — | — | — |
| Research and development | 65.58M USD | 63.64M USD | 57.25M USD | 42.2M USD | 23.81M USD |
| Selling, general, and administrative | 28.16M USD | 30.55M USD | 36.54M USD | 16.8M USD | 11.69M USD |
| Operating expenses | 89.45M USD | 94.18M USD | 84.53M USD | 59M USD | 35.49M USD |
| Interest income | — | — | — | 947K USD | — |
| Interest expense | — | — | — | 118K USD | — |
| Depreciation and amortization | 4.28M USD | 3.57M USD | 3.63M USD | 2.51M USD | 1.6M USD |
| Operating income | −87.34M USD | −91.91M USD | −84.53M USD | −59M USD | −35.49M USD |
| Net income | −117.26M USD | −83.58M USD | −81.17M USD | −58.03M USD | −21.96M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$15.00
42.99% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 6, 2023 | 1:50 | — | — |
Effective Nov 6, 2023
1:50
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM2.84M0.00%78.56B USD0.19%$277.7-1.29%
Vanguard Morningstar Total Stock Market ETFVTI2.44M0.00%2.3T USD0.03%$381.03-0.40%
Vanguard Extended Market ETFVXF879.54K0.00%95.4B USD0.05%$233.49-1.56%
Vanguard Russell 2000 ETFVTWO799.88K0.00%18B USD0.06%$112.21-1.26%
F/M Emerald Life Sciences Innovation ETFLFSC676.02K0.59%116M USD0.79%$41.8366-0.65%
Vanguard Health Care ETFVHT357.23K0.00%22B USD0.09%$315.31+0.78%
iShares Micro-Cap ETFIWC341.66K0.03%1.33B USD0.60%$183.36-1.09%
Avantis U.S. Small Cap Equity ETFAVSC154.11K0.01%3.08B USD0.25%$69.63-1.18%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOF/M Emerald Life Sciences Innovation ETFLFSCVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
